Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer

Nature Clinical Practice Oncology

Volumn 5, Issue 8, 2008, Pages 455-465

  Vincenzi, Bruno ^a   Schiavon, Gaia ^a   Pantano, Francesco ^a   Santini, Daniele ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BILIRUBIN; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; FLUOROURACIL; FOLIC ACID; FOLINATE CALCIUM; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; HEMOGLOBIN; HOMOCYSTEINE; IRINOTECAN; LEVAMISOLE; METHYLMALONIC ACID; MONOCLONAL ANTIBODY; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; PEMETREXED; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNINDEXED DRUG;

AFRICAN AMERICAN; AGE; ANOREXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DYSESTHESIA; FATIGUE; FEVER; GENDER; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INFECTION; LETHARGY; LEUKOPENIA; LOW DRUG DOSE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PREDICTION; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WESTERN HEMISPHERE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; GLUTAMATES; GUANINE; HUMANS; NEOPLASM STAGING; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 48749114973     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1137     Document Type: Review

References (103)

1. Jemal A et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
2. Machover D (1997) A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80: 1179-1187
3. Rustum YM et al. (1997) Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors. J Clin Oncol 15: 389-400
4. Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308
5. Popescu RA et al. (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17: 2412-2418
6. André T et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Mad 350: 2343-2351
7. Cote JF et al. (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13: 3269-3275
8. Watanabe T et al. (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344: 1196-1206
9. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT 132) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17: 1356-1363
10. [No authors listed] (1994) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer: Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 12: 960-969
11. André T et al. (2007) Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon Cancer patients: Final results of GERCOR C96.1. J Clin Oncol 25: 3732-3738
12. Buroker TR et al. (1994) Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14-20
13. Saltz LB et al. for the Irinotecan Study Group (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914
14. Douillard JY et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355 1041-1047
15. Levi F et al. (1997) Randomised multicentre trial of oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350: 681-686
16. Sargent DJ et al. (2001) Recommendation for caution with irinotecan fluorouracil and leucovorin for colorectal cancer. N Eng J Med 345: 690-692
17. Vanhoefer U et al. (2001) Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 19: 1501-1518
18. Blanke C et al. (1997) Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 15: 915-920
19. Wadler S et al. (1989) Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769-1775
20. Poon M et al. (1991) Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972
21. The Meta-Analysis Group in Cancer (1998) Toxicity of fluorouracil with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537-3541
22. Simmonds PC et al. for the Colorectal Cancer Collaborative Group (2000) Palliative chemotherapy for advanced colorectal cancer systematic review and meta-analysis. BMJ 321: 531-535
23. Sloan JA et al. (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20: 1491-1498
24. Stein BN et al. (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer 75: 11-17
25. Milano G et al. (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10: 1171-1175
26. Zalcberg J et al. for the Tomudex International Study Group (1998) Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Cancer 34: 1871-1875
27. Meyerhardt JA et al. (2004) Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer findings from Intergroup Trial 0114. J Clin Oncol 22: 648-657
28. Meyerhardt JA et al. (2003) Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21: 433-440
29. McCollum AD et al. (2002) Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 94: 1160-1167
30. Mattison LK et al. (2006) Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 12: 5491-5495
31. Lu Z et al. (1992) Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 267: 17102-17109
32. Diasio RB (1998) The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 12 (Suppl 7): S23-S27
33. Heggie GC et al. (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206
34. Harris BE et al. (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201
35. Lu Z et al. (1995) Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 58: 512-522
36. van Kuilenburg AB et al. (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene. Clin Cancer Res 6: 4705-4712
37. Raida M et al. (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 50-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7: 2832-2839
38. Milano G et al. (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79: 627-630
39. Johnson MR et al. (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5: 2006-2011
40. van Kuilenburg AB et al. (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency Clin Cancer Res 7: 1149-1153
41. Wei X et al. (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98: 610-615
42. Diasio RB et al. (1988) Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Investig 81: 47-51
43. Capitain O et al. (2007) The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J [doi: 10.1038/sj.tpj.6500476]
44. Kaneda S et al. (1987) Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res 15: 1259-1270
45. Horie N et al. (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20 191-197
46. Marsh S et al. (2000) Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 16: 528
47. Pullarkat ST et al. (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1: 65-70
48. Lecomte T et al. (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10: 5880-5888
49. Santini D et al. (2004) Thymidylate synthase expression in normal colonic mucosa: A predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. Oncology 67: 135-142
50. Ueland PM et al. (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22: 195-201
51. Schwahn B and Rozen R (2001) Polymorphisms in the methylenetetrahydrofolate reductase gene: Clinical consequences. Am J Pharmacogenomics 1: 189-201
52. Bagley PJ and Selhub J (1998) A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 95: 13217-13220
53. Stevenson JP et al. (2001) Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol 19: 4081-4087
54. Toffoli G et al. (2000) MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Ann Oncol 11 373-374
55. Toffoli G et al. (2000) Pharmacogenetics in cancer chemotherapy: 677C-T methylenetetra-hydrofolate reductase (MTHFR) gene polymorphism and toxicity after cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). Clin Cancer Res 6: 4555s
56. Ichikawa W et al. (2006) Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 12: 3928-3934
57. Twelves C et al. (1996) Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies [abstract #1509]. In Proceedings of the American Society of Clinical Oncology Annual Meeting: 1996 May 18-21, Philadelphia, PA. Alexandria, VA: ASCO Publications
58. Terashima M et al. (2002) Toxicity of oral fluoropyrimidines is predictable by dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cell [abstract #617]. In Proceedings of the American Society of Clinical Oncology Annual Meeting: 2002 May 18-21, Orlando, FL. Alexandria, VA: ASCO Publications
59. Jensen SA et al. (2007) The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 120: 694-701
60. Sharma R et al. (2006) A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/ metastatic colorectal cancer. Br J Cancer 94: 964-968
61. Kim R et al. (1992) Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50: 760-766
62. Slichenmyer WJ et al. (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291
63. Tanizawa A et al. (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842
64. Hertzberg RP et al. (1989) Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715-720
65. Kawato Y et al. (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191
66. Kojima A et al. (1993) Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes. Jpn J Clin Oncol 23: 116-22
67. Araki E et al. (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84: 697-702
68. Ohno R et al. (1990) An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907-1912
69. Negoro S et al. (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83 1164-1168
70. Sasaki Y et al. (1995) Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 86: 111-116
71. Iyer L et al. (1997) UGT isoform 1.1 (UGT1°1) glucuronidates SN 38, the active metabolite of irinotecan [abstract #707]. In Proceedings of the American Society of Clinical Oncology Annual Meeting: 1997 May 17-20, Denver, CO. Alexandria, VA: ASCO publications
72. Iyer L et al. (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of UGT 1AQ in the glucuronidation of its active metabolite (SN38) in human liver microsomes. J Clin Invest 101: 847-854
73. Monaghan G et al. (1996) Genetic variation in bilirubin UDP-glycuronyltransferase gene promoter and Gilbert's syndrome. Lancet 347: 578-581
74. Beutler E et al. (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter - a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95: 8170-8174
75. Iyer L et al. (2002) UGT1A1°28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-47
76. Wasserman E et al. (1997) Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports. Ann Oncol 8: 1049-1051
77. Massacesi C et al. (2006) Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106: 1007-1016
78. Chabot GG et al. (1998) Irinotecan pharmacokinetics. Bull Cancer 11-20
79. Chu XY et al. (1998) Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters. Cancer Res 58: 5137-5143
80. Romero RZ et al. (2006) Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol Rep 16: 497-503
81. Boige V et al. (1998) Irinotecan: Various administration schedules, study of drug combinations, phase I experience. Bull Cancer 26-32
82. Extra JM et al. (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303
83. Meyerhardt JA et al. (2004) Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 22: 1439-1446
84. Grothey A (2005) Clinical management of oxaliplatinassociated neurotoxicity. Clin Colorectal Cancer 5 (suppl 1): S38-S46
85. Raymond E et al. (1998) Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 9: 1053-1071
86. Santini D et al. (2003) Recurrent episodes of involuntary masticatory spasms induced by continuous infusion of oxaliplatin. J Natl Cancer Inst 95: 1555-1556
87. De Gramont A et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
88. Brienza S et al. (1995) Oxaliplatin (L-OHP): Global safety in 682 patients [abstract #595]. In Proceedings of the American Society of Clinical Oncology Annual Meeting: 1995 May 31-June 3, Chicago, IL. Alexandria, VA: ASCO Publications
89. Adelsberger H et al. (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406: 25-32
90. Screnci D et al. (2000) Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82: 966-972
91. Takimoto CH et al. (2007) Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 13: 4832-4839
92. Grolleau F et al. (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85: 2293-2297
93. Allain P et al. (2000) Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 28: 1379-1384
94. Takimoto CH et al. (2003) Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 21: 2664-2672
95. Graham MA et al. (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6: 1205-1218
96. Feliu J et al. (2002) Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: An active and low toxicity regimen. Eur J Cancer 38: 1204-1211
97. Romiti A et al. (2002) Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer. Anticancer Res 22: 3071-3076
98. Raderer M et al. (2000) Fatal liver failure after the administration of raltitrexed for cancer chemotherapy: A report of two cases. Cancer 89: 890-892
99. Zalcberg J (1997) Overview of the tolerability of 'Tomudex' (raltitrexed): Collective clinical experience in advanced colorectal cancer. Anticancer Drugs 8 (suppl 2): S17-S22
100. Massacesi C et al. (2003) Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Anticancer Drugs 14: 533-541
101. Rinaldi DA et al. (1996) A phase I evaluation of LY231514, a novel multitargeted antifolate, administered every 21 days [abstract # 1559]. In Proceedings of the American Society of Clinical Oncology Annual Meeting: 1996 May 18-21, Philadelphia, PA. Alexandria, VA: ASCO Publications
102. Niyikiza C et al. (1997) LY231514 (MTA): Relationship of vitamin metabolite profile to toxicity [abstract #2139]. In Proceedings of the American Society of Clinical Oncology Annual Meeting: 1997 May 17-20, Denver, CO. Alexandria, VA: ASCO Publications
103. Niyikiza C et al. (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1: 545-552